Medicine and Dentistry
Melanoma
100%
Neoplasm
83%
Malignant Neoplasm
54%
Cancer
53%
Immunotherapy
47%
Connective Tissue Cancer
40%
Immunity
35%
T Cell
34%
Clinical Trial
32%
Next Generation Sequencing
27%
Lung Cancer
25%
Diseases
24%
Overall Survival
23%
Targeted Therapy
22%
Uvea Melanoma
21%
Tumor Progression
21%
Melanoma Skin Cancer
21%
Melanoma Cell
20%
Colorectal Carcinoma
20%
In Vitro
20%
Soft Tissue Sarcoma
19%
Programmed Cell Death
19%
The Cancer Genome Atlas
19%
Metastatic Carcinoma
18%
Progression Free Survival
18%
MEK Inhibitor
17%
extracellular signal regulated kinase
17%
Tumor Cell
16%
Cytotoxic T-Cell
16%
Cancer Cell
13%
Trametinib
12%
RNA Sequence
12%
Metastatic Melanoma
12%
Gene Expression
12%
Gene Mutation
11%
Cell Proliferation
10%
Cell Survival
10%
Cholangiocarcinoma
10%
Metastatic Uvea Melanoma
10%
Immune Response
10%
Oncology
9%
Pancreas Adenocarcinoma
9%
Carcinogenesis
9%
Cell Migration
9%
Mammalian Target of Rapamycin
9%
positron emission tomographic scan
9%
Immune Checkpoint Inhibitor
8%
Chondrosarcoma
8%
Systemic Therapy
8%
Gene Expression Profiling
8%
Keyphrases
Tumor
48%
Melanoma
46%
Sarcoma
25%
MEK Inhibitor (MEKi)
23%
Mammalian Target of Rapamycin (mTOR)
22%
T Cells
21%
Metastatic Melanoma
21%
In Cancer
21%
Melanocytic Tumor
18%
Genetic Modification
17%
Neoantigen
17%
Trametinib
16%
Uveal Melanoma
16%
Cancer Genome Atlas
16%
Colorectal Cancer
16%
BRAF Inhibitor (BRAFi)
16%
Melanoma Cells
16%
Targeted Therapy
15%
Tumor Subtype
15%
Malignancy
15%
Lung Cancer
14%
Tumor Growth
14%
Overall Survival
14%
Vemurafenib
14%
Tumor Cells
13%
Immune Response
13%
Cancer Cells
13%
MD Anderson Cancer Center
13%
Inducible Nitric Oxide Synthase
13%
Pan-cancer
13%
Solid Tumors
13%
Gene Expression
12%
Molecular Analysis
12%
Melanoma Patients
12%
Non-small Cell Lung Cancer (NSCLC)
12%
Tumor Microenvironment
12%
IDH mutation
11%
Cancer Types
11%
Tumorigenesis
11%
Metastasis
10%
Cholangiocarcinoma
10%
Programmed Death-ligand 1 (PD-L1)
10%
Clinical Trials
10%
Immune Checkpoint Inhibitors
9%
Pediatric
9%
Tumor Protein p53 (TP53)
9%
BRAFV600
9%
Cell Survival
9%
MPGES-1
9%
BRAF V600E mutation
9%
Biochemistry, Genetics and Molecular Biology
Genomics
48%
T Cell
44%
Immunity
35%
Gene Expression
25%
Cancer Cell
24%
Next Generation Sequencing
21%
Immune Checkpoints
21%
Synthase
16%
Clinical Trial
16%
Ubiquitin
15%
Carcinogenesis
15%
Drive
15%
Tumor Progression
15%
Pan-cancer
14%
Wild Type
14%
Mammalian Target of Rapamycin
13%
Gene Mutation
13%
Programmed Cell Death
12%
Peptidase
12%
Vemurafenib
12%
Mesenchymal-Epithelial Transition
12%
Progression Free Survival
12%
Prostaglandin E2
12%
Tumor-Infiltrating Lymphocytes
12%
Mouse Model
11%
RNA Sequence
11%
Messenger RNA
10%
extracellular signal regulated kinase
10%
Antigen Presentation
10%
Long Non-Coding RNA
9%
Oncogene
9%
Overall Survival
9%
DNA Methylation
9%
CD8
9%
Cell Proliferation
9%
Synapse
8%
CD74
8%
Fluorescence Resonance Energy Transfer
8%
Photobleaching
8%
RNA Editing
8%
Monosomy
8%
Polyploid
8%
Human Leukocyte Antigen
8%
Adolescence
8%
Cell Death
8%
Immune Response
7%
Histone
7%
T Cell Receptor
7%
Enzyme
7%
Cytotoxic T Cell
7%
